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Routine versus clinically driven laboratory monitoring of HIV 
antiretroviral therapy in Africa (DART): a randomised 
non-inferiority trial 
DART Trial Team*
Summary 
Background HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; 
however, the eﬀ ect of this approach is unknown. This trial investigated whether routine toxicity and eﬃ  cacy monitoring 
of HIV-infected patients receiving ART had an important long-term eﬀ ect on clinical outcomes in Africa. 
Methods In this open, non-inferiority trial in three centres in Uganda and one in Zimbabwe, 3321 symptomatic, ART-
naive, HIV-infected adults with CD4 counts less than 200 cells per μL starting ART were randomly assigned to 
laboratory and clinical monitoring (LCM; n=1659) or clinically driven monitoring (CDM; n=1662) by a computer-
generated list. Haematology, biochemistry, and CD4-cell counts were done every 12 weeks. In the LCM group, results 
were available to clinicians; in the CDM group, results (apart from CD4-cell count) could be requested if clinically 
indicated and grade 4 toxicities were available. Participants switched to second-line ART after new or recurrent WHO 
stage 4 events in both groups, or CD4 count less than 100 cells per μL (LCM only). Co-primary endpoints were new 
WHO stage 4 HIV events or death, and serious adverse events. Non-inferiority was deﬁ ned as the upper 95% 
conﬁ dence limit for the hazard ratio (HR) for new WHO stage 4 events or death being no greater than 1·18. Analyses 
were by intention to treat. This study is registered, number ISRCTN13968779.
Findings Two participants assigned to CDM and three to LCM were excluded from analyses. 5-year survival was 87% 
(95% CI 85–88) in the CDM group and 90% (88–91) in the LCM group, and 122 (7%) and 112 (7%) participants, 
respectively, were lost to follow-up over median 4·9 years’ follow-up. 459 (28%) participants receiving CDM versus 
356 (21%) LCM had a new WHO stage 4 event or died (6·94 [95% CI 6·33–7·60] vs 5·24 [4·72–5·81] per 
100 person-years; absolute diﬀ erence 1·70 per 100 person-years [0·87–2·54]; HR 1·31 [1·14–1·51]; p=0·0001). 
Diﬀ erences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line 
treatment occurred in LCM from the second year. 283 (17%) participants receiving CDM versus 260 (16%) LCM had 
a new serious adverse event (HR 1·12 [0·94–1·32]; p=0·19), with anaemia the most common (76 vs 61 cases).
Interpretation ART can be delivered safely without routine laboratory monitoring for toxic eﬀ ects, but diﬀ erences in 
disease progression suggest a role for monitoring of CD4-cell count from the second year of ART to guide the switch to 
second-line treatment.
Funding UK Medical Research Council, the UK Department for International Development, the Rockefeller 
Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories.
Introduction
The unprecedented expansion of antiretroviral therapy 
(ART) in Africa has been achieved in settings with poor 
health infrastructure, and often without access to routine 
laboratory monitoring for toxic eﬀ ects or eﬃ  cacy. 
Whether treatment programmes should provide 
laboratory monitoring or focus resources on continuing 
to expand access to ﬁ rst-line and second-line ART is a 
crucial debate in the present economic crisis.1,2 
In resource-rich countries, patients receiving ART have 
routine (typically every 3 months) tests to monitor eﬃ  cacy 
and toxic eﬀ ects. This testing is not mandated in public 
health ART rollout3—the approach underpinning many 
African treatment programmes—because it needs 
high-technology laboratory services and substantial 
resources. In fact, the eﬀ ect of routine laboratory 
monitoring, in addition to good clinical care, has been 
formally assessed only in one trial in Uganda (data not 
published4). This information is crucial for policy makers 
and implementers. If routine laboratory tests do not add 
signiﬁ cant beneﬁ t, ART programmes would be open to 
decentralisation with long-term follow-up in local clinics 
rather than distant hospitals, providing that con sistent and 
good quality care could be provided. Laboratory services 
could be targeted to assessment for ART eligibility and to 
diagnosis and management of opportunistic infec tions or 
clinical toxicity, rather than being done routinely. 
The Development of AntiRetroviral Therapy in Africa 
(DART) trial was therefore designed to investigate whether 
delivery of ART with or without routine monitoring of 
CD4-cell counts for eﬃ  cacy, and haematology and 
biochemistry for safety, led to similar outcomes in HIV-
infected patients receiving ART who had already fulﬁ lled 
clinical and CD4-count criteria to start ART. 
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Methods
Study design and participants
DART was an open randomised trial enrolling 
symptomatic (WHO stage 2–4) HIV-infected adults 
(≥18 years) with CD4 counts less than 200 cells per μL 
who reported no previous ART apart from to prevent 
mother-to-child transmission. Participants were enrolled 
between Jan 15, 2003, and Oct 24, 2004, from centres in 
Uganda (Medical Research Council/Uganda Virus 
Research Institute [UVRI] Uganda Research Unit on 
AIDS, Entebbe; Joint Clinical Research Centre, Kampala; 
and satellite Infectious Diseases Institute, Mulago) and 
Zimbabwe (University of Zimbabwe, Harare). Exclusion 
criteria were: cannot, or unlikely to attend regular 
follow-up (eg, usual residence too far from study centre); 
likelihood of poor compliance; presence of acute 
infection (patients could be admitted after recovery of 
an acute infection) or on intensive phase of 
antituberculosis therapy; receiving chemotherapy for 
malignant disease; laboratory abnormalities that were a 
contraindication for the patient to start ART (eg, 
haemoglobin concentration <80 g/L, neutrophils 
<0·50×10⁹/L, alanine amino trans ferase [ALT] or 
aspartate aminotransferase  [AST] more than ﬁ ve times 
the upper limit of normal, grade 3 renal dysfunction 
[creatinine >360 μmol/L or urea more than ﬁ ve times 
the upper limit of normal]); and pregnancy or 
breastfeeding. Participants gave written consent both 
for screening and, if eligible, enrolment. The trial was 
approved by research ethics committees in Uganda, 
Zimbabwe, and the UK.
Randomisation and masking
At enrolment all participants received triple-drug ART (co-
formulated zidovudine-lamivudine [GlaxoSmithKline, 
Ware, UK] plus tenofovir disoproxil fumarate [Gilead 
Science, Foster City, CA, USA], abacavir [GlaxoSmithKline, 
Ware, UK], or nevirapine [Boehringer Ingelheim, 
Ingelheim, Germany]) and were randomly assigned to 
receive clinically driven monitoring (CDM) or laboratory 
plus clinical monitoring (LCM) for toxic eﬀ ects 
(haematology and biochemistry) and eﬃ  cacy (CD4-cell 
counts). HIV viral loads were not done in real-time, in 
accordance with WHO guidelines5 and national norms. 
The hypothesis was that CDM would result in similar 
outcomes to LCM (non-inferiority). 600 participants were 
randomly assigned to diﬀ erent ﬁ rst-line ART regimens in 
the nested Nevirapine OR Abacavir (NORA) substudy 
(placebo-controlled to NORA primary endpoint of toxicity 
at 24 weeks6); all other participants received open-label 
ﬁ rst-line ART. A further partial factorial randomisation 
within DART comparing structured treatment interr-
uptions with continuous ART in 813 participants with CD4 
counts greater than 300 cells per μL after 48 or 72 weeks on 
continuous ART ended in March, 2006.7 
Randomisation was stratiﬁ ed by centre, screening 
CD4 count (0–99 vs 100–199 cells per μL), and ﬁ rst-line 
ART (tenofovir disoproxil fumarate vs nevirapine vs 
randomisation in NORA). The computer-generated 
sequentially numbered randomisation list (with variable 
block sizes) was preprepared by the trial statistician and 
securely incorporated within the database at each trial 
centre, connected to but not located within each clinical 
centre, allowing trial managers to access the next number 
but not the whole list. Randomisation was undertaken by 
clinicians phoning the local trials centre. 
Procedures
All participants saw a doctor and had a routine full blood 
count with white cell diﬀ erential, lymphocyte subsets 
(CD4, CD8), and liver and renal function tests (bilirubin, 
urea, creatinine, AST/ALT) at screening, weeks 4 and 12, 
and then every 12 weeks. All results for LCM participants 
were returned to clinicians, whereas results after enrol-
ment for CDM participants were returned only if 
requested for clinical reasons (reviewed and authorised 
3257 not randomised
2754 protocol exclusion criteria*
1906 CD4 count >200 cells per μL
390 acute opportunistic infection
258 laboratory abnormality
92 unlikely to attend regularly 
78 likelihood of poor compliance
17 pregnant
6 on chemotherapy
5 disclosed previous ART 
2 HIV negative on retesting 
503 other reason
399† did not attend next visit
67 declined to consent
37 enrolment closed
6578 participants screened
3321 randomly assigned
1662 allocated to CDM 1659 allocated to LCM
1656 analysed
2 excluded because randomised 
in error‡
1 excluded because randomised twice 
1660 analysed
2 excluded because randomised 
twice
1660 initiated ﬁrst-line ART 
2 did not return after enrolment 
and not known to have died
122 not known to have died and last 
seen alive before Dec 31, 2008 
(end of study)
74 last seen alive in 2007 or earlier
17 withdrew consent 
218 died before Dec 31, 2008
1656 initiated ﬁrst-line ART
4 did not return after enrolment 
and not known to have died
112 not known to have died and last 
seen alive before Dec 31, 2008
(end of study)
69 last seen alive in 2007 or earlier
22 withdrew consent 
164 died before Dec 31, 2008
Figure 1: Trial proﬁ le
CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. ART=antiretroviral therapy. *Main 
reason for ineligibility. †221 (55%) participants subsequently returned and were rescreened. ‡One participant had 
taken ART before starting the trial, and was not prescribed trial drugs or followed up; one individual without a 
consent form at monitoring defaulted before 8 weeks.
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by each centre project leader) or if there was 
grade 4 laboratory toxic eﬀ ects (protocol safety criteria, 
grades deﬁ ned in protocol according to minor modi-
ﬁ cations of the AIDS Clinical Trials Group criteria8). No 
total lymphocyte or CD4-cell counts were returned for 
participants assigned to CDM. For all participants, 
diagnostic investigations and other laboratory tests (apart 
from CD4-cell count and total lymphocytes for CDM) 
could be requested, and concomitant drugs prescribed, 
as clinically indicated. All participants received ART and 
were reviewed by a nurse every 4 weeks (with use of a 
standard symptom checklist). 
Antiretroviral drugs could be substituted, preferably 
within class, for adverse events. The decision to switch to 
second-line ART (with a ritonavir-boosted protease 
inhibitor) was based on clinical criteria in both groups 
(new or recurrent WHO stage 4 event; or WHO stage 3 
event such as candidosis or weight loss at clinician 
discretion), or on laboratory criteria for LCM (conﬁ rmed 
CD4 count <100 cells per μL on ART [<50 cells per μL 
before July, 2006]). Following WHO guidelines,9 switching 
before 48 weeks was discouraged.
Participants were followed up under CDM or LCM 
strategies until Dec 31, 2008. At their next visit in 
January, 2009, participants assigned to CDM received all 
masked results, and those with low CD4-cell counts 
(following WHO guidelines9) were switched to second-line 
ART. 
Study outcomes 
The co-primary endpoints were (1) progression to a new 
WHO stage 4 HIV event or death,10 and (2) serious 
adverse events, which were deﬁ ned as events not related 
only to HIV and either fatal, life-threatening, causing 
unplanned or prolonged admission to hospital, causing 
permanent or signiﬁ cant disability, or other import-
ant medical conditions.11 Laboratory or clinical 
grade 4 adverse events did not have to be reported as 
serious adverse events unless they met one of these 
criteria. Secondary endpoints were: mortality; pro-
gression to a new or recurrent WHO stage 4 HIV event 
or death; any grade 3 or 4 adverse events; number and 
class of antiretroviral drugs received; time to second-line 
regimen; adherence measured by questionnaire and pill 
counts; CD4-cell counts; HIV RNA viral load and 
resistance (done retrospectively); and cost-eﬀ ectiveness 
(reported separately). All WHO stage 4 events, deaths, 
and serious adverse events were reviewed against 
prespeciﬁ ed criteria by an Endpoint Review Committee 
with an independent chair and members, all of whom 
were masked to randomised allocation.
Statistical analysis
Interim data for safety, adherence to randomised 
strategies, and eﬃ  cacy of CDM and LCM were reviewed 
regularly by an independent Data Safety and Monitoring 
Committee, which met every 9–12 months (seven 
meetings in total). The Haybittle-Peto criterion, p<0·001,12 
was the statistical guide for considering recommending 
stopping or modifying the trial. 
The planned sample size of 3300 adults followed up for 
4–6 years provided 80% power to establish that CDM was 
not inferior to LCM. Non-inferiority was deﬁ ned as the 
upper 95% conﬁ dence limit for the hazard ratio (HR; 
CDM:LCM) for new WHO stage 4 events or death being 
no greater than 1·18, which is equivalent to a yearly rate 
of progression of no more than 11·8 per 100 person-years 
in CDM compared with a predicted rate of 10·0 per 
100 person-years in LCM.
Clinically driven 
monitoring 
(n=1660)
Laboratory and 
clinical monitoring 
(n=1656)
Centre
Entebbe, Uganda 511 (31%) 509 (31%)
Joint Clinical Research Centre, Uganda 499 (30%) 498 (30%)
Infectious Disease Unit, Uganda 151 (9%) 149 (9%)
Harare, Zimbabwe 499 (30%) 500 (30%)
Women 1064 (64%) 1092 (66%)
Reported likely transmission route sex between men and women 1648 (99%) 1639 (99%)
Age (years), median (range) 36 (18–73) 36 (18–67)
CD4-cell count (cells per μL), median (range) 86 (1–199) 86 (0–199)
0–49 cells per μL 555 (33%) 554 (33%)
HIV-1 RNA (log10 copies per mL)* 5·4 (0·7) 5·4 (0·7)
WHO stage
2 310 (19%) 363 (22%)
3 948 (57%) 916 (55%)
4 402 (24%) 377 (23%)
Previous oral or oesophageal candidosis 856 (52%) 831 (50%)
Weight (kg) 57·6 (10·6) 57·9 (10·6)
Body-mass index (kg/m²) 21·7 (3·9) 21·7 (3·8)
Haemoglobin (g/L) 115 (17) 115 (18)
Glomerular ﬁ ltration rate (mL/min/1·73 m²)† 95·0 (35·0) 92·3 (28·9)
On co-trimoxazole prophylaxis at or before randomisation 1034 (62%) 1014 (61%)
First-line ART: zidovudine and lamivudine plus
Tenofovir disoproxil fumarate 1237 (75%) 1232 (74%)
Abacavir (randomised in NORA‡) 150 (9%) 150 (9%)
Nevirapine (randomised in NORA‡) 150 (9%) 150 (9%)
Open-label nevirapine 123 (7%) 124 (7%)
Identiﬁ ed at any time (including after baseline) as having 
previously received ART for any reason§
65 (4%) 65 (4%)
Antiretroviral drugs to prevent mother-to-child transmission 
(% of women)¶ 
38 (4%) 23 (2%)
Data are n (%) or mean (SD), unless otherwise indicated. ART=antiretroviral therapy. NORA=Nevirapine OR Abacavir 
substudy. *968 patients (not chosen at random; 473 in CDM group vs 495 in LCM group); all participants randomised 
in NORA plus a substudy in participants receiving tenofovir disoproxil fumarate as ﬁ rst-line treatment.13 †Calculated 
according to the Cockcroft-Gault formula14 and adjusted for body surface area. ‡Nested factorial randomised substudy, 
blinded to 24 weeks. §Including ART to prevent mother-to-child transmission, disclosure of previous ART during the 
trial (unsolicited or solicited at switch to second-line treatment), presence of any nucleoside reverse transcriptase 
inhibitor or non-nucleoside reverse transcriptase inhibitor mutation or major protease inhibitor mutation on baseline 
resistance test (467 [14%] patients assayed to date; 225 in CDM group vs 242 in LCM group), or disclosure from speciﬁ c 
question on 4-year form (2741 patients completed; 1348 in CDM group vs 1393 in LCM group). ¶Single-dose 
nevirapine (n=56; 33 in CDM group vs 23 in LCM group) or zidovudine (n=5; ﬁ ve in CDM group vs none in LCM group). 
Table: Characteristics at randomisation (ART initiation)
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Kaplan-Meier plots, log-rank test, and proportional 
hazards models, stratiﬁ ed by randomisation stratiﬁ  cation 
factors, were used to compare randomised groups for 
time-to-event outcomes, censoring at the earlier of 
Dec 31, 2008, or last follow-up. Categorical variables were 
com pared between randomised groups with χ² or exact 
tests, and continuous variables with t tests or rank-sum 
tests. All comparisons between groups were as ran dom-
ised (intention to treat). Baseline values were those 
nearest to but before and within 42 days of random-
isation. Generalised estimating equations (independent 
corre la tion structure) were used to compare laboratory 
measure ments and adherence across randomised groups 
over time, with the closest measurement to each 
scheduled visit within equally spaced intervals. All 
p values are two-sided. 
This study is registered, number ISRCTN13968779.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. 3321 participants were 
enrolled. Three participants randomised twice (at 
diﬀ erent centres) were included from their ﬁ rst 
randomisation, and two with major eligibility violations 
were excluded, leaving 3316 participants in the ﬁ nal 
intention-to-treat analysis (ﬁ gure 1). Baseline charac-
teristics were similar between groups (table).
Median follow-up to Dec 31, 2008, or the time last seen 
alive was 4·9 years (IQR 4·4–5·3) in the CDM group and 
4·9 years (4·5–5·3) in the LCM group. Follow-up was 
14 937 person-years (7404 person-years in CDM group 
and 7533 in LCM group; maximum 6 years), of which 
only 6 person-years in 12 participants (ﬁ ve in CDM group, 
seven in LCM group) was spent oﬀ  the allocated 
monitoring strategy (viral load and/or CD4-cell count 
[CDM only] monitoring elsewhere but still providing 
follow-up data through medical records). Only 234 (7%) 
participants were lost to follow-up before Dec 31, 2008, 
and not known to have died (ﬁ gure 1). Completeness of 
nurse visits every 4 weeks and doctor visits every 12 weeks 
was high and similar in both groups (nurse visits 97·7% 
[95 271/97 525] in CDM group vs 97·8% [97 066/99 221] in 
LCM group; doctor visits 98·7% [40 525/41 056] vs 98·8% 
[41 086/41 602]). 
Clinicians managing participants assigned to CDM 
could request individual results from the routine 
biochemistry or haematology panels (every 12 weeks) for 
clinical reasons. These haematology or biochemistry 
panels could also be requested, if clinically indicated, at 
inter vening nurse visits every 4 weeks and extra patient-
initiated visits in both groups. Most of the tests done from 
these panels were undertaken at routine visits every 12 
weeks (<8% at nurse/extra visits for haematology and <5% 
for biochemistry panels; webappendix p 1). In the CDM 
group, very few (<4%) individual results were released 
(webappendix p 1), most often haemoglobin, neutrophils, 
creatinine, and urea. Overall, more additional investigations 
were requested during nurse or extra visits in the LCM 
group than in the CDM group: 812 (49%) participants 
assigned to CDM and 965 (58%) to LCM had one or more 
additional haematology tests (p<0·0001); and 639 (38%) 
assigned to CDM and 683 (41%) to LCM had one or more 
additional biochemistry tests (p=0·11). 635 (38%) CDM 
and 633 (38%) LCM participants had one or more other 
(non-routine panel) blood tests (p=0·99), mostly other 
biochemistry (eg, electrolytes).
At Dec 31, 2008, or last clinic visit, 1346 (81%) people 
receiving CDM versus 1295 (78%) receiving LCM were 
still on ﬁ rst-line ART, including 288 (17%) CDM and 
281 (17%) LCM participants who had substituted one or 
more ﬁ rst-line drugs (rates 7·4 [95% CI 6·8–7·5] and 7·6 
[7·0–8·3] per 100 person-years, respectively). Adverse 
events led to 859 of 1037 (83%) ﬁ rst-line substitutions 
(427 in CDM group and 432 in LCM group; participants 
could substitute more than once in ﬁ rst-line treatment), 
with the remainder due to concomitant anti tuberculosis 
therapy (81 [8%]; 44 in CDM group and 37 in LCM group) 
or other reasons (eg, pregnancy; data not shown). 
Adherence by self-reported questionnaire every 4 weeks 
was similar in both groups, with 3·5% (3164/90 233) 
reports in the CDM group versus 3·3% (2995/91 979) in 
the LCM group of missing pills in the last 4 days (p=0·14), 
and 8·5% (7692/90 929) versus 7·8% (7256/92 656) in the 
last 28 days (p=0·45).
Number alive in
follow-up on
ﬁrst-line ART
LCM
CDM
HR=1·06 (95% CI 0·91–1·23), p=0·44
HR=0·84 (95% CI 0·72–0·98), p=0·03 Not switched
to second-line
regimen
Ever substituted
to alternate
ﬁrst-line
regimen
CDM
LCM
Years from randomisation (ART initiation)
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Figure 2: Substitution in ﬁ rst-line ART and switch to second-line ART
Percentages of participants still on ﬁ rst-line antiretroviral therapy (ART) and ever substituted to an alternate 
ﬁ rst-line regimen were estimated with cumulative incidences (deaths on ﬁ rst-line therapy were treated as 
competing risks, as was switch to second-line ART for ﬁ rst-line substitutions). Cause-speciﬁ c hazard models in 
which deaths (and switch to second-line ART for ﬁ rst-line substitutions) are censored were used to calculate hazard 
ratios, stratiﬁ ed by randomisation factors. HR=hazard ratio. CDM=clinically driven monitoring. LCM=laboratory 
and clinical monitoring.
See Online for webappendix
Articles
www.thelancet.com   Vol 375   January 9, 2010 127
Overall, 314 (19%) people receiving CDM versus 
361 (22%) receiving LCM switched to second-line ART 
(ﬁ gure 2). Switching was more frequent in the LCM 
group than in the CDM group in the second (HR 0·48 
[95% CI 0·33–0·71]) and third (0·77 [0·58–1·01]) years 
after starting ART, but was more similar in the fourth 
(0·90 [0·67–1·20]), ﬁ fth (1·36 [0·98–1·88]), and sixth 
(1·10 [0·44–2·73]) years (overall heterogeneity p value 
over years on ART p=0·001). 6% of follow-up time to last 
ART assessment (471/7397 person-years) was spent on 
second-line treatment in CDM group versus 9% in LCM 
group (700/7528 person-years). 
459 (28%) CDM participants versus 356 (21%) LCM 
participants had a new WHO stage 4 event or died (6·94 
[95% CI 6·33–7·60] and 5·24 [4·72–5·81] per 
100 person-years, respectively). The absolute diﬀ erence 
of 1·70 per 100 person-years (95% CI 0·87–2·54) 
translated into a relative HR of 1·31 (95% CI 1·14–1·51; 
p=0·0001; ﬁ gure 3). The upper (but not lower) 95% 
conﬁ dence limit was greater than the predeﬁ ned 
non-inferiority margin of 1·18. 
New WHO stage 4 event-free survival at 5 years was 
72% (95% CI 70–74) in the CDM group versus 78% (76–80) 
in the LCM group, and the number needed to monitor for 
1 year to avoid one event was 59. 62% (408/654) of all new 
WHO stage 4 events and 65% (248/382) of deaths occurred 
in the ﬁ rst 2 years. In a prespeciﬁ ed subgroup analysis, 
event rates were similar in CDM and LCM groups during 
the ﬁ rst 90 days (29·6 [95% CI 24·7–35·5] vs 30·8 [25·7–
36·8] per 100 person-years), 90 days to 1 year (7·2 [5-8–
8·9] vs 7·0 [5·6–8·7] per 100 person-years), and the second 
year (5·4 [4·3–6·7] vs 4·4 [3·4–5·6] per 100 person-years) 
on ART. From the third year, event rates continued to 
decrease in both groups, but were 1·5–2·0-fold higher in 
the CDM than in the LCM group (6·0 [4·8–7·5] vs 3·1 
[2·3–4·2] per 100 person-years in the third year, 4·9 
[3·8–6·3] vs 2·6 [1·8–3·6] per 100 person-years in the 
fourth year, 4·3 [3·2–5·9] vs 2·1 [1·4–3·2] per 
100 person-years in the ﬁ fth year; heterogeneity p=0·001). 
65% of the diﬀ erence between CDM and LCM in time to 
ﬁ rst new WHO stage 4 event or death was explained by 
adjusting for latest CD4-cell count, suggesting that the 
later switching leading to lower CD4-cell group in the 
CDM group was driving the diﬀ erences between groups. 
Similar results were obtained for new or recurrent 
WHO stage 4 event-free survival (HR 1·27 [95% CI 
1·11–1·46]; p=0·0004). Oesophageal candidosis (178/452 
[39%] in CDM group vs 100/328 [30%] in LCM group), 
cryptococcosis (87/452 [19%] vs 69/328 [21%] LCM group), 
and extrapulmonary tuberculosis (76/452 [17%] vs 72/328 
[22%]) were the most common new or recurrent WHO 
stage 4 events, with the largest diﬀ erence between groups 
in oesophageal candidosis. 
218 (13%) CDM versus 164 (10%) LCM participants 
died (2·9 [95% CI 2·6–3·4] vs 2·2 [1·9–2·5] per 
100 person-years, respectively; absolute diﬀ erence 
0·77 per 100 person-years [0·25–1·28], ﬁ gure 3). 5-year 
survival with ART was 87% (95% CI 85–88) in the CDM 
group versus 90% (88–91) in the LCM group, and the 
number needed to monitor for 1 year to avoid one death 
was 130. 105 deaths in the CDM group versus 71 in the 
LCM group were judged to be mainly HIV-related; and 
eight versus 11 deaths to be mainly drug-related (ART or 
concomitant). 
CD4-cell counts increased throughout the trial 
(ﬁ gure 4), with 82% (551/672) of CDM and 86% 
(623/728) of LCM participants having CD4 counts 
greater than 200 cells per μL at week 264 (5·1 years, 
n=1400). Median CD4 counts for the 2337 participants 
last seen alive on ﬁ rst-line ART was 339 cells per μL 
(IQR 225–467) in the CDM group and 372 cells per μL 
(251–499) in the LCM group, with 81 of 1178 (7%) versus 
22 of 1159 (2%), respectively, having CD4 counts less 
than 100 cells per μL (ﬁ gure 4). More CDM than LCM 
participants also had low CD4-cell counts at death on 
ﬁ rst-line treatment. At switch to second-line treatment, 
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Figure 3: Clinical disease progression (A) and adverse events (B)
All hazard ratios were stratiﬁ ed according to randomisation factors, and p values were calculated with the log-rank 
test. Number needed to monitor for 1 year to avoid one (ﬁ rst) event was 130 (death) and 59 (new WHO stage 4 
event of death) participants. Survival p values were 0·95 at 1 year, 0·92 at 3 years, and 0·90 at 5 years for laboratory 
and clinical monitoring (LCM) group; 0·94, 0·90, and 0·87 for clinically driven monitoring (CDM) group; and 0·55, 
0·18, and 0·08 for the Entebbe15 cohort, respectively. HR=hazard ratio. ART=antiretroviral therapy. *Data from 
HIV-infected population of similar disease stage between 1996 and 2000.
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151 of 314 (48%) CDM versus 145 of 361 (40%) LCM 
participants had CD4 count less than 50 cells per μL; 
64 (20%) CDM participants who switched did so with 
CD4 counts greater than 250 cells per μL compared 
with only seven (2%) LCM participants.
Despite large diﬀ erences in the number of laboratory 
toxicity tests in the two groups, the proportion of 
participants having one or more serious adverse events 
(co-primary endpoint) was similar (283 [17%] in CDM 
group vs 260 [16%] in LCM group; ﬁ gure 3). The most 
common type was hospital admissions (266/650 serious 
adverse events: 155 in CDM and 111 in LCM groups), and 
the most common diagnosis was anaemia (137/650 
serious adverse events: 76 in CDM and 61 in LCM groups, 
webappendix p 2). 422 (25%) CDM participants and 
416 (25%) LCM participants had adverse events leading to 
ﬁ rst-line or second-line ART modiﬁ cation (HR 1·01 [95% 
CI 0·88–1·16]; p=0·86), with anaemia the most common 
cause (312/1252 modiﬁ cations; 173 in CDM group vs 
139 in LCM group) followed by lipodystrophy or 
lipoatrophy (113 vs 128) and neutropenia (81 vs 124). 
Similar proportions of participants had one or more grade 
3 or 4 adverse events (1168 [70%] in CDM group vs 
1151 [70%] in LCM group) or grade 4 adverse events 
(683 [41%] vs 643 [39%]). However, most grade 3–4 adverse 
events (2617/3533 [74%] vs 2024/3024 [67%]) and many 
individual grade 4 adverse events (592/1223 [48%] vs 
442/1004 [44%]) were laboratory toxicity without clinical 
symptoms, most frequently neutropenia.
Discussion
DART was designed as a large non-inferiority trial with 
suﬃ  cient power to establish whether routine toxicity and 
eﬃ  cacy monitoring on ART had an important long-term 
eﬀ ect on clinical outcomes in Africa. The results clearly 
show that ﬁ rst-line ART can be delivered safely without 
routine biochemistry and haematology monitoring for 
toxic eﬀ ects, but that routine CD4-cell count monitoring 
has a small but signiﬁ cant beneﬁ t in terms of disease 
progression and mortality, probably owing to slightly 
earlier switching to second-line ART. 
In the original trial design, clinically relevant inferiority 
was predeﬁ ned as a small increase in new WHO stage 4 
events or death from 10 per 100 person-years in the LCM 
group to 11·8 per 100 person-years in the CDM group. To 
show that the eﬀ ect of CDM was no more than this 
increase was regarded as an acceptable deﬁ nition of 
non-inferiority; given the likely costs of routine laboratory 
monitoring, small diﬀ erences would be unlikely to be 
cost eﬀ ective and given the potential of CDM to allow 
wider ART rollout in Africa. CDM was clearly not 
non-inferior, with a signiﬁ cant increase recorded in 
disease progression and death. However, since the 
95% CI for the co-primary endpoint new WHO stage 4 
event or death included our predeﬁ ned non-inferiority 
margin, we also cannot formally state that CDM was 
inferior. 
CDM in DART was not implemented as no laboratory 
monitoring—all participants had a CD4-cell count done to 
establish eligibility for ART, and participants assigned to 
CDM could have investigations and blood tests (apart from 
CD4-cell count) that are necessary to manage clinical 
episodes, as could be feasible outside a trial setting. Indeed, 
with well supervised and supported clinical care that is 
freely available to participants, 87% survival at 5 years was 
achieved in the CDM group—much better than predicted 
given that a third of participants had CD4 count less than 
50 cells per μL at ART initiation, and among the best 
reported in Africa16–18 and worldwide.19,20 This ﬁ nding clearly 
shows that good ART outcomes with low mortality can be 
attained without routine laboratory monitoring. 
Irrespective of monitoring strategy, overall survival at 
5 years was 88% (death rate 2·56 per 100 person-years). 
The huge survival beneﬁ ts from ART are well documented 
by historical comparison within the Entebbe centre17 
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Figure 4: CD4-cell counts
(A) Mean absolute CD4-cell count with time (unadjusted). CD4-cell counts were done every 12 weeks—small 
decreases at weeks 60, 84, and 108 are a result of the structured treatment interruption randomisation 
(terminated). Increase in mean CD4 count in the ﬁ rst 12 weeks was 102 cells per μL (95% CI 98–106) in clinically 
driven monitoring (CDM) group versus 103 cells per μL (99–107) in laboratory and clinical monitoring (LCM) 
group (p=0·77). Mean increase per year was subsequently 35 cells per μL (33–37) in CDM group and 42 cells per μL 
(40–44) in LCM group (p<0·0001). (B) Last CD4-cell count on ﬁ rst-line antiretroviral therapy (ART) or at switch to 
second-line ART. Number of deaths was 82 during the ﬁ rst year on ﬁ rst-line ART and 37 in the second year in LCM 
group and 97 during the ﬁ rst year on ﬁ rst-line ART and 32 in the second year in CDM group.
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(ﬁ gure 3). More than 80% of participants started ART 
with triple nucleoside reverse transcriptase inhibitors, 
allaying concerns that these regimens have suboptimum 
clinical eﬃ  cacy. High loss to follow-up can underestimate 
mortality, but with the very high retention sustained 
through 6 years, we are conﬁ dent that the trial results are 
robust. Although quality of care might vary between ART 
programmes, and rarely matches that provided in well 
resourced clinical trials, we see no reason why the 
additional eﬀ ect of routine laboratory monitoring should 
depend on the level of care provided. If anything, the 
interpretation of routine laboratory results by less well 
trained and supervised health-care workers with little 
access to diagnostic services and in-patient facilities 
would tend to weaken the usefulness of the results and 
provide relatively less beneﬁ t than the small diﬀ erences 
recorded here. 
Routine haematology and biochemistry toxicity laboratory 
monitoring did not aﬀ ect time to ﬁ rst serious adverse 
event, grade 3–4 or 4 adverse event, or ART-modifying toxic 
eﬀ ects. First-line substitution rates were similar across 
groups, with about 20% of participants using alternative or 
substituted ﬁ rst-line regimens at 5 years. These results 
should be generalisable to all currently used ﬁ rst-line 
regimens, given that stavudine toxic eﬀ ects are mostly 
clinical (ie, would not be likely to be aﬀ ected by routine 
laboratory monitoring for toxic eﬀ ects) and that more than 
900 DART participants took nevirapine, 547 from the start 
of ART. The number of additional tests done was generally 
greater in the LCM group than in the CDM group, 
suggesting that routine monitoring promotes, rather than 
prevents, extra tests being done. 
Routine eﬃ  cacy monitoring with CD4 tests every 
12 weeks had no discernible eﬀ ect in the ﬁ rst year on 
ART, but resulted in higher rates of switch to second-line 
therapy from the second year on ART, small but signiﬁ cant 
decreases in the proportion of person-years spent with 
low CD4-cell counts, and lower rates of HIV disease 
progression and death from the third year on ART (but 
not before) than in CDM. Of note, a ﬁ fth of participants 
assigned to CDM with clinically-identiﬁ ed failure had 
CD4 counts greater than 250 cells per μL, conﬁ rming 
previous reports that laboratory and clinical failure criteria 
do not always agree.21,22 Although small compared with 
the eﬀ ect of ART, the identiﬁ ed beneﬁ ts of CD4-cell count 
monitoring are highly unlikely to be attributable to 
chance, and further assessment of less frequent CD4 
measurements (eg, every 6 months) and targeted CD4-
cell counts to conﬁ rm immunological failure at suspected 
clinical failure is needed. All DART participants had CD4-
cell counts measured before ART initiation and were 
screened for haematological and biochemical abnormal-
ities. DART cannot therefore inform the debate about use 
of CD4-cell counts to establish eligibility for ART or the 
value of routine pre-ART laboratory screening.
In a parallel, individual-patient, cost-eﬀ ectiveness 
analysis (data not published), routine laboratory 
monitoring every 12 weeks for toxic eﬀ ects was 
particularly expensive. In the LCM group, early switching 
to second-line ART, although lowering costs of hospital 
admissions, resulted in signiﬁ cantly greater costs of 
second-line drugs. Therefore overall costs of CDM were 
much lower than were those of LCM, and LCM, as 
implemented in DART, was not cost eﬀ ective on the 
basis of present WHO recommendations for sub-
Saharan Africa of three times gross domestic product 
per head23—about US$1200 in Uganda and Zimbabwe. 
Further continuing sensitivity analyses are exploring the 
cost-eﬀ ectiveness of scenarios, including routine CD4-
cell count but not laboratory monitoring for toxic eﬀ ects 
while on ART. If budget constraints necessitate choices 
in where best to allocate scarce resources, our data 
suggest that a greater public health eﬀ ect would be 
gained from widening access to ART for untreated 
patients with low CD4-cell counts who are at high risk of 
mortality rather than providing routine laboratory 
monitoring for people already receiving ART.
DART has several potential limitations. Randomisation 
was open, although members of the Endpoint Review 
Committee were masked to allocation. Although 
clinicians were encouraged to report all potential 
endpoints, WHO stage 4 events might have been 
under-reported in LCM participants with higher CD4-cell 
counts; however, this would reduce diﬀ erences between 
groups in event-free survival. In the few instances in 
which CDM participants reported obtaining external 
CD4-cell counts during the trial, clinicians remained 
masked. In a survey at DART exit, only 81 of 1281 (6%) 
CDM participants reported having CD4-cell counts done 
privately, half having only one test. Finally, real-time viral 
load testing was not feasible when DART started. Detailed 
analyses of viral load and resistance assays undertaken 
on stored specimens are in progress, and will inform the 
debate about how best to use these tests in ART 
programmes in Africa.
Few studies are available with which to compare DART 
results. The randomised HBAC trial compared clinical 
monitoring with CD4-cell monitoring and with CD4-cell 
plus virological monitoring in more than 900 patients 
followed up for 3 years.4 Investigators reported that the 
use of routine CD4-cell count monitoring was associated 
with fewer new AIDS-deﬁ ning events or death than was 
clinical monitoring alone, which is a similar ﬁ nding to 
DART. However, switching rates were highest in the 
clinical group, making interpretation diﬃ  cult. A modelling 
study also projected very small diﬀ erences between 
virological, CD4-cell count, and clinical monitoring 
strategies to 5 years.24
DART results have major implications for ART 
programmes in Africa at a time when there is uncertainty 
about long-term funding and sustainability and when 
most people still cannot access treatment.25 We have 
shown that routine laboratory monitoring for toxic eﬀ ects 
in HIV patients receiving ART has no beneﬁ t. ART can be 
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delivered safely with good quality clinical care, allowing 
treatment delivery to be decentralised. Small diﬀ erences 
in disease progression suggest a role for CD4-cell testing 
from the second year on ART to guide the switch to 
second-line ART and should encourage accelerated 
development of simpler, cheaper, point-of-care CD4 tests. 
Laboratories will remain important for assessment of 
eligibility for ART, in terms of CD4-cell count and 
contraindications for speciﬁ c drugs, and for diagnosis and 
management of opportunistic infections and clinical 
toxicity. With less need to provide routine monitoring, 
particularly for toxicity, funding can be focused on drug 
procurement, strengthening of diagnostic laboratory 
services, and training and supervision for health-care 
workers to foster quality clinical monitoring, to support 
scale-up of ART rollout to rural Africa where 60% of the 
HIV-infected population live.
Contributors
The DART trial was designed by C F Gilks, P Mugyenyi, J Hakim, 
A Reid, D Bray, J H Darbyshire, D M Gibb, and A G Babiker. The trial 
was undertaken in Uganda by P Mugyenyi, H Grosskurth, E Katabira, 
C Kityo, P Munderi, and F Ssali; and in Zimbabwe by J Hakim and 
A Reid. The trial was coordinated in the UK by D M Gibb, C F Gilks, 
A G Babiker, and A S Walker. A S Walker and A G Babiker wrote the trial 
analysis plan, which all authors then reviewed; and A S Walker did the 
analyses. All authors contributed to interpretation of the data. 
A S Walker wrote the ﬁ rst draft of the paper with D M Gibb, 
A G Babiker, J H Darbyshire, and C F Gilks. All authors revised the 
report critically and approved the ﬁ nal version. 
DART Trial Team
Asterisk indicates staﬀ  who left during DART. Analysis and Writing 
Committee P Mugyenyi, A S Walker, J Hakim, P Munderi, D M Gibb, 
C Kityo, A Reid, H Grosskurth, J H Darbyshire, F Ssali, D Bray, 
E Katabira, A G Babiker, C F Gilks. MRC/UVRI Uganda Research Unit on 
AIDS, Entebbe, Uganda H Grosskurth, P Munderi, G Kabuye, 
D Nsibambi, R Kasirye, E Zalwango, M Nakazibwe, B Kikaire, 
G Nassuna, R Massa, K Fadhiru, M Namyalo, A Zalwango, L Generous, 
P Khauka, N Rutikarayo, W Nakahima, A Mugisha, J Todd, J Levin, 
S Muyingo, A Ruberantwari, P Kaleebu, D Yirrell, N Ndembi, F Lyagoba, 
P Hughes, M Aber, A Medina Lara, S Foster, J Amurwon, 
B Nyanzi Wakholi, J Whitworth*, K Wangati*, B Amuron*, D Kajungu*, 
J Nakiyingi*, W Omony*, K Fadhiru*, D Nsibambi*, P Khauka*. Joint 
Clinical Research Centre, Kampala, Uganda P Mugyenyi, C Kityo, F Ssali, 
D Tumukunde, T Otim, J Kabanda, H Musana, J Akao, H Kyomugisha, 
A Byamukama, J Sabiiti, J Komugyena, P Wavamunno, S Mukiibi, 
A Drasiku, R Byaruhanga, O Labeja, P Katundu, S Tugume, P Awio, 
A Namazzi, G T Bakeinyaga, H Katabira, D Abaine, J Tukamushaba, 
W Anywar, W Ojiambo, E Angweng, S Murungi , W Haguma, S Atwiine, 
J Kigozi, L Namale*, A Mukose*, G Mulindwa*, D Atwiine*, 
A Muhwezi*, E Nimwesiga*, G Barungi*, J Takubwa*, S Murungi*, 
D Mwebesa*, G Kagina*, M Mulindwa*, F Ahimbisibwe*, P Mwesigwa*, 
S Akuma*, C Zawedde*, D Nyiraguhirwa*, C Tumusiime*, L Bagaya*, 
W Namara*, J Kigozi*, J Karungi*, R Kankunda*, R Enzama*. University 
of Zimbabwe, Harare, Zimbabwe A Latif*, J Hakim, V Robertson, A Reid, 
E Chidziva, R Bulaya-Tembo, G Musoro, F Taziwa, C Chimbetete, 
L Chakonza, A Mawora, C Muvirimi, G Tinago, P Svovanapasis, 
M Simango, O Chirema, J Machingura, S Mutsai, M Phiri, T Bafana, 
M Chirara, L Muchabaiwa, M Muzambi, J Mutowo, T Chivhunga, 
E Chigwedere*, M Pascoe*, C Warambwa*, E Zengeza*, F Mapinge*, 
S Makota*, A Jamu*, N Ngorima*, H Chirairo*, S Chitsungo*, 
J Chimanzi*, C Maweni*, R Warara*, M Matongo*, S Mudzingwa*, 
M Jangano*, K Moyo*, L Vere*, N Mdege*, I Machingura*. Infectious 
Diseases Institute (formerly the Academic Alliance) Makerere University, 
Mulago, Uganda E Katabira, A Ronald, A Kambungu, F Lutwama, 
I Mambule, A Nanfuka, J Walusimbi, E Nabankema, R Nalumenya, 
T Namuli, R Kulume, I Namata, L Nyachwo, A Florence, A Kusiima, 
E Lubwama, R Nairuba, F Oketta, E Buluma, R Waita, H Ojiambo, 
F Sadik, J Wanyama, P Nabongo, J Oyugi*, F Sematala*, A Muganzi*, 
C Twijukye*, H Byakwaga*. The AIDS Support Organisation (TASO), 
Uganda R Ochai, D Muhweezi, A Coutinho*, B Etukoit*. Imperial College, 
London, UK C Gilks, K Boocock, C Puddephatt, C Grundy, J Bohannon, 
D Winogron*. MRC Clinical Trials Unit, London, UK D M Gibb, A Burke, 
D Bray, A Babiker, A S Walker, H Wilkes, M Rauchenberger, S Sheehan, 
C Spencer-Drake, K Taylor, M Spyer, A Ferrier, B Naidoo, D Dunn, 
R Goodall, JH Darbyshire, L Peto*. Independent DART Trial Monitors 
R Nanfuka, C Mufuka-Kapuya. DART Virology Group P Kaleebu 
(Co-Chair), D Pillay (Co-Chair), V Robertson, D Yirrell, S Tugume, 
M Chirara, P Katundu, N Ndembi, F Lyagoba, D Dunn, R Goodall, 
A McCormick. DART Health Economics Group A Medina Lara (Chair), 
S Foster, J Amurwon, B Nyanzi Wakholi, J Kigozi, L Muchabaiwa, 
M Muzambi. Trial Steering Committee I Weller (Chair), A Babiker (Trial 
Statistician), S Bahendeka, M Bassett, A Chogo Wapakhabulo, 
J H Darbyshire, B Gazzard, C Gilks, H Grosskurth, J Hakim, A Latif, 
C Mapuchere, O Mugurungi, P Mugyenyi; Observers C Burke, S Jones, 
C Newland, G Pearce, S Rahim, J Rooney, M Smith, W Snowden, 
J-M Steens. Data and Safety Monitoring Committee A Breckenridge 
(Chair), A McLaren (previous Chair-deceased), C Hill, J Matenga, 
A Pozniak, D Serwadda. Endpoint Review Committee T Peto (Chair), 
A Palfreeman, M Borok, E Katabira. 
Conﬂ icts of interest 
All members of the Analysis and Writing Committee declare that they 
have no conﬂ icts of interest. 
Acknowledgments
We thank all the patients and staﬀ  from all the centres participating in 
the DART trial. DART was funded by the UK Medical Research Council, 
the UK Department for International Development (DFID), and the 
Rockefeller Foundation. GlaxoSmithKline, Gilead Sciences, and 
Boehringer-Ingelheim donated ﬁ rst-line drugs for DART, and Abbott 
Laboratories provided LPV/r (Kaletra/Aluvia) as part of the second-line 
regimen for DART.
References 
1 UNAIDS. The global economic crisis and HIV prevention and 
treatment programmes: vulnerabilities and impact. June, 2009. 
http://data.unaids.org/pub/Report/2009/jc1704_econcrisis_
hivresponse_en.pdf (accessed Dec 2, 2009).
2 World Bank. Averting a human crisis during the global downturn: 
policy options from the World Bank’s Human Development Network. 
2009. http://siteresources.worldbank.org/NEWS/Resources/
AvertingTheHumanCrisis.pdf (accessed Dec 2, 2009).
3 Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health 
approach to antiretroviral treatment against HIV in 
resource-limited settings. Lancet 2006; 368: 505–10.
4 Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, 
CD4 cell count, and clinical monitoring among HIV-infected adults 
in Uganda: a randomized trial. 15th Conference on Retroviruses 
and Opportunistic Infections. Boston, MA, USA; Feb 3–6, 2008. 
Abstract 125.
5 WHO. Antiretroviral therapy for HIV infection in adults and 
adolescents in resource-limited settings: towards universal access. 
Recommendations for a public health approach. Geneva: World 
Health Organization, 2006.
6 Dart Trial Team. Twenty-four-week safety and tolerability of 
nevirapine vs. abacavir in combination with zidovudine/lamivudine 
as ﬁ rst-line antiretroviral therapy: a randomized double-blind trial 
(NORA). Trop Med Int Health 2008; 13: 6–16.
7 Dart Trial Team. Fixed duration interruptions are inferior to 
continuous treatment in African adults starting therapy with 
CD4 cell counts <200 cells/microl. AIDS 2008; 22: 237–47.
8 Division of AIDS. Table for grading severity of adult adverse 
experiences. Bethesda: National Institute of Allergy and Infectious 
Diseases, 1992. 
9 WHO. Antiretroviral therapy for HIV infection in adults and 
adolescents in resource-limited settings: towards universal access. 
Recommendations for a public health approach. Geneva: World 
Health Organization, 2006.
10 Interim proposal for a WHO Staging System for HIV infection and 
Disease. Wkly Epidemiol Rec 1990; 65: 221–24.
Articles
www.thelancet.com   Vol 375   January 9, 2010 131
11 International conference on harmonisation of technical requirements 
for registration of pharmaceuticals for human use. Clinical safety data 
management: deﬁ nitions and standards for expedited reporting 
(E2A); 1994. http://www.emea.europa.eu/pdfs/human/ich/037795en.
pdf (accessed Dec 2, 2009). 
12 Peto R, Pike MC, Armitage P, et al. Design and analysis of 
randomized clinical trials requiring prolonged observation of each 
patient. I. Introduction and design. Br J Cancer 1976; 34: 585–612.
13 Dart Virology Group and Trial Team. Virological response to a triple 
nucleoside/nucleotide analogue regimen over 48 weeks in 
HIV-1-infected adults in Africa. AIDS 2006; 20: 1391–99. 
14 Cockcroft DW, Gault MH. Prediction of creatinine clearance from 
serum creatinine. Nephron 1976; 16: 31–41.
15 Munderi P, Watera C, Nakiyingi J, et al. Survival and causes of 
death, 2 years after introduction of antiretroviral therapy in Africa: 
a historical cohort comparison in Entebbe, Uganda. XVI 
International AIDS Conference. Toronto, Canada; Aug 13–18, 2006. 
Abstract THLB0208.
16 Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early 
mortality in South Africa. Bull World Health Organ 2008; 86: 678–87.
17 Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of 
initial patients treated in Botswana’s National Antiretroviral 
Treatment Program. AIDS 2008; 22: 2303–11.
18 Lawn SD, Little F, Bekker LG, et al. Changing mortality risk 
associated with CD4 cell response to antiretroviral therapy in South 
Africa. AIDS 2009; 23: 335–42.
19 Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China 
National Free Antiretroviral Treatment Program. 
Ann Intern Med 2009; 151: 241–51, W-52.
20 Leger P, Charles M, Severe P, Riviere C, Pape JW, Fitzgerald DW. 
5-year survival of patients with AIDS receiving antiretroviral therapy 
in Haiti. N Engl J Med 2009; 361: 828–29.
21 Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public 
health approach to identify antiretroviral therapy failure: high-level 
nucleoside reverse transcriptase inhibitor resistance among 
Malawians failing ﬁ rst-line antiretroviral therapy. AIDS 2009; 
23: 1127–34.
22 Kantor R, Diero L, Delong A, et al. Misclassiﬁ cation of ﬁ rst-line 
antiretroviral treatment failure based on immunological monitoring 
of HIV infection in resource-limited settings. Clin Infect Dis 2009; 
49: 454–62.
23 Medina Lara A, Kigozi J, Amurwon J, et al. Cost eﬀ ectiveness 
analysis of routine laboratory or clinically driven strategies for 
monitoring anti-retroviral therapy in Uganda and Zimbabwe 
(DART Trial). 5th IAS Conference on HIV Pathogenesis, Treatment 
and Prevention. Cape Town, South Africa; July 19–22, 2009. 
Abstract TUSS103.
24 Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, 
Lundgren JD. Outcomes from monitoring of patients on 
antiretroviral therapy in resource-limited settings with viral load, 
CD4 cell count, or clinical observation alone: a computer simulation 
model. Lancet 2008; 371: 1443–51.
25 WHO. Towards universal access: scaling up priority HIV/AIDS 
interventions in the health sector: a progress report. http://www.
who.int/hiv/pub/2009progressreport/en/index.html 
(accessed Oct 18, 2009).
